Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
One-year comparison of rivaroxaban, apixaban, and warfarin in atrial fibrillation
IRCT20220404054402N1Phase 2Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of rivaroxaban, apixaban and warfarin in Atrial fibrillation (AFib) (3 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoints: Minor and major bleeding, Ischemic stroke and 1 more. Started Jun 2022; status: completed.
02
Drugs
rivaroxabanapixabanwarfarin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on IRCT20220404054402N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220404054402N1.